SARS-Cov-2


08/18/2022


  • Recently declined stock price of BNTX and MRNA may be caused by Dr. Ashish Jha's comments.


Dr. Ashish Jha commented that Biden administration would soon end the acute emergency phase of pandemic and stopped buying the COVID-19 related vaccines, drugs and tests at the event sponsored by the US Chamber of Commerce Foundation.

He also said that commercialization of almost all of these products should be available in 2023. (not emergency authorization any more)

Listen the whole conversation click here.




08/17/2022



Joint Committee on Vaccination and Immunisation of UK recommended age of 5 and above to get booster shot from all available booster.




Published in JAMA and Report from EXPRESS

04/20/2022


Update 04/21/2022 report from Forbes


EXPRESS reported vaccine study of 23 million shows real risk of 'heart problems' from Moderna or Pfizer jab.

  • Study 23 million in 4 Nordic countries. 81% study subjects vaccinated by study end.

  • The chance of myocarditis and pericarditis is higher in vaccinated than unvaccinated. Read full report click here.


Original publication from JAMA. Read original publication click here.

  • 23,122,522 Nordic residents

  • 1077 incident myocarditis and 1149 incident pericarditis

  • vaccinated male of age 16-24 has much higher risk of the problems

  • Myocarditis events per 100,000 vaccinees:

    • All males -

      • BNTX, 0.27 after 1st dose, 0.67 after 2nd dose;

      • MRNA, 0.33 after 1st dose, 4.97 after 2nd dose.

    • All females -

      • BNTX, 0.15 after 1st dose, 0.09 after 2nd dose;

      • MRNA, 0.05 after 1st dose, 0.48 after 2nd dose.

    • Males age 16-24 -

      • BNTX, 1.55 after 1st dose, 5.55 after 2nd dose;

      • MRNA, 1.75 after 1st dose, 18.39 after 2nd dose.

    • With Covid infected unvaccinated -

      • all males 3.26,

      • males age 16-24 1.37.

However, regulators and experts overwhelmingly agree that the benefits of vaccines outweigh the possible risks. Reported from Forbes.




Published in NEJM and Report from BENZINGA

04/18/2022


BZ (BENZINGA) reports that studies from Israel shows Pfizer/BioNTech 4th Covid vaccine dose protect against Omicron for at least one month. The effectiveness of 4th dose was estimated 45% against infection, 55% against symptomatic Covid disease, 68% against hospitalization, 62% against severe illness, and 74% against death for age of 60 or older after 7-30 days of administrating 4th dose vaccine. Read full report click here.

Read the original report from which BZ reported click here (04/13/2022).




Published in Bloomberg

04/05/2022


The African Union and Covax declined the options to purchase additional Covid-19 vaccines from Moderna Inc.

  • The African Union would not exercise the option to purchase vaccines of 60 million dose for the second quarter of 2022, addition to the delivery of 55 million doses in the first quarter of 2022.

  • Also, Covax declined two options to purchase two additional 166 million doses of Covid-19 vaccine, 332 million doses in total, for delivery in third and fourth quarter of 2022.



Published in The New England Journal of Medicine

03/30/2022


Effect of Early Treatment with Ivermectin among Patients with Covid-19




Published in The New England Journal of Medicine

03/23/2022


Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection



Report from CNN

02/24/2022

Sanofi, GSK seeks approval of COVID vaccine for 2-dose stand alone and third dose as booster.

Of course, this is a not-so-good news for Moderna, BioNTech, even Johnson & Johnson. However, maybe there is a silver lining. Why do those giant pharmaceuticals keeps getting into the seemingly crowded field of COVID-19 prevention/treatment if there is an end of COVID-19 as some medical experts and analysts suggest? Or there is no actual ending of COVID-19, and human has to live with SARS-cov-2 with vaccination/treatment and annual surge of cases?




The New England Journal of Medicine

02/03/2022

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Please keep in mind that 1. The sample size is small. 2. There is significant difference of the mean days of sample (mean 165.6 days from samples of participants with two doses vaccines and mean 25 days from sample of recipients with 3 doses vaccines.

The next point to focus is the durability of the effect of third dose of vaccine against COVID-19 as the article points out. If there is going to have another surge wave of COVID-19, the war against SARS-cov-2 is clearer.




CDC

01/19/2022

The studies of COVID-19 cases in NY and CA from 05/30/2021 to 11/20/2021 find the Delta variant changes the protection of COVID-19 vaccine:
vaccinated with previous infection > unvaccinated with previous infection > vaccinated with no previous infection > unvaccinated with no previous infection.

However, the studies have limitation, such as severity of previous infection is not included.


01/07/2022 FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months after shorten interval for booster dose from BioNTech to 5 months on Monday

Examining the chart of new COVID-19 cases from South Africa (reason of choice, larger country & population and less vaccinated, clear and distinct waves of case surge), the intervals of waves (4th wave now) almost coincides with the time frame of diminishing power of antibodies against SARS-cov-2 (please review the information in studies of BioNTech and Moderna). Combining with the studies of additional shots from Israel, it will become clearer and clearer that a five-month-shot is needed or not. More and more studies have been confirming that waning antibodies is a certain. Will the wave of COVID-19 surge be related to the waning antibodies if SARS-Cov-2 decides to stay with us?


When Three Shots Are Not Enough - From New York Times

The interesting parts in this article are what Israel are doing and the flexibility to implement additional shoots for individual need.